HomeCompareASPCF vs PLD

ASPCF vs PLD: Dividend Comparison 2026

ASPCF yields 909.59% · PLD yields 3.18%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 ASPCF wins by $8291491.26M in total portfolio value
10 years
ASPCF
ASPCF
● Live price
909.59%
Share price
$0.22
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$8291497.77M
Annual income
$6,817,159,983,407.13
Full ASPCF calculator →
PLD
PLD
● Live price
3.18%
Share price
$128.78
Annual div
$4.10
5Y div CAGR
74.4%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$6.50M
Annual income
$5,256,436.18
Full PLD calculator →

Portfolio growth — ASPCF vs PLD

📍 ASPCF pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodASPCFPLD
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, ASPCF + PLD cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
ASPCF pays
PLD pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

ASPCF
Annual income on $10K today (after 15% tax)
$77,314.90/yr
After 10yr DRIP, annual income (after tax)
$5,794,585,985,896.06/yr
PLD
Annual income on $10K today (after 15% tax)
$270.62/yr
After 10yr DRIP, annual income (after tax)
$4,467,970.75/yr
At 15% tax rate, ASPCF beats the other by $5,794,581,517,925.31/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of ASPCF + PLD for your $10,000?

ASPCF: 50%PLD: 50%
100% PLD50/50100% ASPCF
Portfolio after 10yr
$4145752.14M
Annual income
$3,408,582,619,921.65/yr
Blended yield
82.22%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on PLD right now

ASPCF
No analyst data
PLD
Analyst Ratings
25
Buy
16
Hold
1
Sell
Consensus: Buy
Price Target
$136.00
+5.6% upside vs current
Range: $119.00 — $155.00
Altman Z
1.9
Piotroski
5/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

ASPCF buys
0
PLD buys
0
No recent congressional trades found for ASPCF or PLD in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricASPCFPLD
Forward yield909.59%3.18%
Annual dividend / share$2.00$4.10
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%74.4%
Portfolio after 10y$8291497.77M$6.50M
Annual income after 10y$6,817,159,983,407.13$5,256,436.18
Total dividends collected$8177275.77M$6.37M
Payment frequencyquarterlyquarterly
SectorStockREIT

Year-by-year: ASPCF vs PLD ($10,000, DRIP)

YearASPCF PortfolioASPCF Income/yrPLD PortfolioPLD Income/yrGap
1← crossover$101,659$90,958.70$11,255$555.24+$90.4KASPCF
2$972,957$864,181.69$13,062$1,018.59+$959.9KASPCF
3$8,770,897$7,729,833.49$15,903$1,926.67+$8.75MASPCF
4$74,508,241$65,123,381.48$20,839$3,823.32+$74.49MASPCF
5$596,751,110$517,027,292.00$30,464$8,166.08+$596.72MASPCF
6$4,508,591,853$3,870,068,165.34$52,054$19,457.30+$4508.54MASPCF
7$32,150,599,702$27,326,406,419.03$109,886$54,188.93+$32150.49MASPCF
8$216,516,638,004$182,115,496,323.36$304,030$186,451.18+$216516.33MASPCF
9$1,377,885,778,910$1,146,212,976,244.92$1,166,125$840,813.32+$1377884.61MASPCF
10$8,291,497,766,840$6,817,159,983,407.13$6,504,190$5,256,436.18+$8291491.26MASPCF

ASPCF vs PLD: Complete Analysis 2026

ASPCFStock

Acerus Pharmaceuticals Corporation, a specialty pharmaceutical company, focuses on the development, manufacture, marketing, and distribution of pharmaceutical products for men's and women's health. The company offers Natesto, a nasal gel for testosterone replacement therapy in adult males diagnosed with hypogonadism; and Noctiva, a vasopressin analog indicated for the treatment of nocturia due to nocturnal polyuria in adults who awaken at least 2 times per night to void. It also engages in developing Lidbree, a short acting lidocaine formulation delivered through a proprietary device into the vaginal mucosal tissue; Stendra, a PDE5 inhibitor for the treatment of erectile dysfunction; Tefina, a clinical stage product for women with female sexual dysfunction; and Noctiva combination products, which are in the pre-clinical development stage for the treatment of benign prostatic hypertrophy, overactive bladder, and pediatric nocturnal enuresis. In addition, the company provides TriVair technology platform for pulmonary and nasal dosing. It sells its products through its salesforce in the United States and Canada; and through a network of distributors internationally. The company was formerly known as Trimel Pharmaceuticals Corporation and changed its name to Acerus Pharmaceuticals Corporation in September 2015. Acerus Pharmaceuticals Corporation was founded in 2008 and is headquartered in Mississauga, Canada.

Full ASPCF Calculator →

PLDREIT

Prologis, Inc. is the global leader in logistics real estate with a focus on high-barrier, high-growth markets. As of December 31, 2020, the company owned or had investments in, on a wholly owned basis or through co-investment ventures, properties and development projects expected to total approximately 984 million square feet (91 million square meters) in 19 countries. Prologis leases modern logistics facilities to a diverse base of approximately 5,500 customers principally across two major categories: business-to-business and retail/online fulfillment.

Full PLD Calculator →
📬

Get this ASPCF vs PLD comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

ASPCF vs SCHDASPCF vs JEPIASPCF vs OASPCF vs KOASPCF vs MAIN

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.